Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:DAWN NYSE:QGEN NASDAQ:RGC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$97.50-0.8%$115.19$5.69▼$148.83$7.84B0.692.93 million shs1.94 million shsDAWNDay One Biopharmaceuticals$21.53$19.41$5.64▼$21.53$2.22B-1.741.52 million shs2.99 million shsQGENQiagen$37.21+0.5%$36.91$32.53▼$57.81$7.67B0.662.03 million shs2.12 million shsRGCRegencell Bioscience$16.73-2.1%$26.21$9.39▼$81.23$8.45B1.6592,615 shs157,391 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax-0.77%-5.08%-14.87%-21.36%+1,350.89%DAWNDay One Biopharmaceuticals0.00%0.00%0.00%+1.03%+224.25%QGENQiagen+0.67%-1.47%+12.75%-8.01%-25.52%RGCRegencell Bioscience-2.11%-17.63%-41.46%-36.58%+1,672,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$97.50-0.8%$115.19$5.69▼$148.83$7.84B0.692.93 million shs1.94 million shsDAWNDay One Biopharmaceuticals$21.53$19.41$5.64▼$21.53$2.22B-1.741.52 million shs2.99 million shsQGENQiagen$37.21+0.5%$36.91$32.53▼$57.81$7.67B0.662.03 million shs2.12 million shsRGCRegencell Bioscience$16.73-2.1%$26.21$9.39▼$81.23$8.45B1.6592,615 shs157,391 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax-0.77%-5.08%-14.87%-21.36%+1,350.89%DAWNDay One Biopharmaceuticals0.00%0.00%0.00%+1.03%+224.25%QGENQiagen+0.67%-1.47%+12.75%-8.01%-25.52%RGCRegencell Bioscience-2.11%-17.63%-41.46%-36.58%+1,672,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 2.73Moderate Buy$130.0833.41% UpsideDAWNDay One Biopharmaceuticals 2.00Hold$23.298.15% UpsideQGENQiagen 2.42Hold$44.9820.87% UpsideRGCRegencell Bioscience 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest DAWN, RGC, QGEN, and ABVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026ABVXAbivax BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$150.006/3/2026ABVXAbivax Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$136.006/3/2026ABVXAbivax Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/2/2026ABVXAbivax Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$140.00 ➝ $135.006/2/2026ABVXAbivax Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$145.00 ➝ $132.006/2/2026ABVXAbivax CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/2/2026ABVXAbivax Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$160.00 ➝ $90.006/2/2026ABVXAbivax Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$131.00 ➝ $187.006/2/2026ABVXAbivax WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderperform ➝ Neutral$110.00 ➝ $90.006/2/2026ABVXAbivax BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$150.005/29/2026QGENQiagen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$6.57 per shareN/ADAWNDay One Biopharmaceuticals$158.18M14.06N/AN/A$4.30 per share5.01QGENQiagen$2.10B3.65$3.42 per share10.87$17.89 per share2.08RGCRegencell BioscienceN/AN/AN/AN/A$0.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$380.27M-$5.21N/AN/AN/AN/A-99.02%-70.26%N/ADAWNDay One Biopharmaceuticals-$107.32M-$1.03N/A2,153.00N/A-67.85%-23.43%-20.69%N/AQGENQiagen$424.88M$1.9119.4314.103.6819.16%14.40%8.40%8/4/2026 (Estimated)RGCRegencell Bioscience-$3.58MN/AN/AN/AN/AN/AN/AN/AN/ALatest DAWN, RGC, QGEN, and ABVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2026Q1 2026ABVXAbivax-$0.9359-$0.71+$0.2259-$0.71$0.40 million$1.56 million5/8/2026Q1 2026RGCRegencell BioscienceN/A-$0.0050N/A-$0.0050N/AN/A5/7/2026Q1 2026QGENQiagen$0.54$0.54N/A$0.33$496.15 million$492.32 million3/23/2026Q4 2025ABVXAbivax-$2.24-$1.20+$1.04-$1.20$1.80 million$0.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AQGENQiagen$0.350.94%N/A18.32%N/ARGCRegencell BioscienceN/AN/AN/AN/AN/ALatest DAWN, RGC, QGEN, and ABVX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/11/2026QGENQiagenannual$0.351.04%7/7/20267/7/20267/14/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivaxN/A8.258.25DAWNDay One BiopharmaceuticalsN/A8.027.91QGENQiagen0.493.212.57RGCRegencell BioscienceN/A1.41N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%DAWNDay One Biopharmaceuticals87.95%QGENQiagen70.00%RGCRegencell Bioscience0.13%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/ADAWNDay One Biopharmaceuticals6.20%QGENQiagen9.00%RGCRegencell BioscienceN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6179.77 millionN/ANot OptionableDAWNDay One Biopharmaceuticals60103.33 million96.93 millionOptionableQGENQiagen5,654206.08 million187.53 millionOptionableRGCRegencell Bioscience10494.49 millionN/AN/ADAWN, RGC, QGEN, and ABVX HeadlinesRecent News About These CompaniesRGC SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026June 16 at 6:29 PM | newsfilecorp.comNREGENCELL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action - RGCJune 16 at 6:27 PM | newsfilecorp.comNPomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers – RGCJune 16 at 3:44 PM | globenewswire.comDEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersJune 16 at 12:16 PM | globenewswire.comPortnoy Law Firm Announces Class Action on Behalf of Regencell Bioscience Holdings Limited InvestorsJune 16 at 11:12 AM | globenewswire.comRGC Shareholder Alert: June 23, 2026 Lead Plaintiff Deadline in Regencell Bioscience Holdings Limited Securities Class Action - Contact The Gross Law FirmJune 16 at 9:13 AM | prnewswire.comRGC INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of the June 23, 2026 Lead Plaintiff Deadline in the Regencell Bioscience Holdings Limited Securities Class ActionJune 16 at 7:30 AM | globenewswire.comRGC DEADLINE ALERT: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Regencell Bioscience ...June 16 at 1:49 AM | caledonianrecord.comCRGC DEADLINE ALERT: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGCJune 15 at 8:32 PM | globenewswire.comRGC DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action - RGCJune 15 at 6:22 PM | newsfilecorp.comNRGC Shareholder Alert: June 23, 2026 Lead Plaintiff Deadline in Regencell Bioscience Holdings Securities Class Action - Contact Levi & KorsinskyJune 15 at 4:04 PM | globenewswire.comRegencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitJune 15 at 3:09 PM | prnewswire.comRGC INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026June 15 at 1:34 PM | newsfilecorp.comNBronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor HarmJune 15 at 12:00 PM | newsfilecorp.comNREGENCELL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action - RGCJune 14 at 6:17 PM | newsfilecorp.comNBronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor HarmJune 14 at 12:00 PM | globenewswire.comREGENCELL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important June 23 Deadline in Securities Class Action - RGCJune 13, 2026 | markets.businessinsider.comREGENCELL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important June 23 Deadline in Securities Class Action - RGCJune 13, 2026 | newsfilecorp.comNRGC EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026June 13, 2026 | globenewswire.comRGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud LawsuitJune 12, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDAWN, RGC, QGEN, and ABVX Company DescriptionsAbivax NASDAQ:ABVX$97.50 -0.76 (-0.77%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$97.87 +0.37 (+0.38%) As of 09:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Day One Biopharmaceuticals NASDAQ:DAWNDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Qiagen NYSE:QGEN$37.21 +0.20 (+0.55%) Closing price 06/16/2026 03:59 PM EasternExtended Trading$37.35 +0.14 (+0.37%) As of 09:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Regencell Bioscience NASDAQ:RGC$16.73 -0.36 (-2.11%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$16.90 +0.18 (+1.05%) As of 09:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Could a Tesla-SpaceX Merger Be Closer Than Investors Think? Strategy’s Bitcoin Rally Has a Hidden Engine Is Lennar Finally Turning the Corner After Its Housing Slump? Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
